MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 526911 | Name: Fostedil

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fostedil, also known as KB-944, is a calcium channel antagonist potentially for the treatment of angina pectoris. KB-944 increased regional segment function in normal and ischemic regions and maintained distal coronary artery perfusion pressure, coronary flow and transmural regional myocardial blood flow during partial coronary artery occlusion despite a reduction in aortic pressure. In a model of total coronary artery occlusion.

Chemical Structure

Fostedil
Fostedil
CAS#75889-62-2

Theoretical Analysis

MedKoo Cat#: 526911

Name: Fostedil

CAS#: 75889-62-2

Chemical Formula: C18H20NO3PS

Exact Mass: 361.0902

Molecular Weight: 361.40

Elemental Analysis: C, 59.82; H, 5.58; N, 3.88; O, 13.28; P, 8.57; S, 8.87

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
KB-944; KB 944; KB944; A 53986; A-53986; BRN 3626546; Fostedil
IUPAC/Chemical Name
diethyl (4-(benzo[d]thiazol-2-yl)benzyl)phosphonate
InChi Key
FVYRUSCZCWSFLT-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H20NO3PS/c1-3-21-23(20,22-4-2)13-14-9-11-15(12-10-14)18-19-16-7-5-6-8-17(16)24-18/h5-12H,3-4,13H2,1-2H3
SMILES Code
O=P(CC1=CC=C(C2=NC3=CC=CC=C3S2)C=C1)(OCC)OCC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 361.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Sekine Y, Hirakawa N, Kashiwaba N, Matsumoto H, Kutsuma T, Yamaura T, Sekine A. A novel histamine 2(H2) receptor antagonist with gastroprotective activity. I. Synthesis and pharmacological evaluation of N-phenoxypropylacetamide derivatives with thioether function. Chem Pharm Bull (Tokyo). 1998 Apr;46(4):610-5. PubMed PMID: 9579036. 2: Tchani G, Baziard-Mouysset G, Stigliani JL, Payard M, Bonnafous R, Tisne-Versailles J. Influence of the vinyl group on the calcium antagonistic activity of analogues of Fostedil. Pharm Acta Helv. 1994 Jan;68(3):173-9. PubMed PMID: 8121926. 3: Rose U. [2-Aryl substituted benzo-anellated 5-ring-heterocycles as potential agents for the cardiovascular system. 2. 1,3-Benzimidazoles]. Pharmazie. 1991 Nov;46(11):775-7. German. PubMed PMID: 1811227. 4: Staudinger R, Knaus HG, Glossmann H. Positive heterotropic allosteric regulators of dihydropyridine binding increase the Ca2+ affinity of the L-type Ca2+ channel. Stereoselective reversal by the novel Ca2+ antagonist BM 20.1140. J Biol Chem. 1991 Jun 15;266(17):10787-95. PubMed PMID: 1645709. 5: Mouysset G, de Saqui-Sannes G, Younes S, Bellan J, Payard M, Tisne-Versailles J. Contribution of the diethyl phosphonate group to a first approach of calcium-inhibiting activity: study of a series of various substituted 2-phenylbenzothiazoles. Farmaco. 1990 Sep;45(9):945-52. PubMed PMID: 2282126. 6: Yoshino K, Goto K, Yoshiizumi K, Morita T, Tsukamoto G. Organic phosphorus compounds. 5. (4-Benzothiazol-2-ylbenzyl)amidophosphonate as potent calcium antagonistic vasodilators. J Med Chem. 1990 Aug;33(8):2192-6. PubMed PMID: 2374146. 7: Yoshino K, Goto K, Kohno T, Morita T, Tsukamoto G. Organic phosphorus compounds. IV. Asymmetric 4-(benzothiazol-2-yl)benzylphosphonates as potent calcium antagonistic vasodilators. Chem Pharm Bull (Tokyo). 1990 Mar;38(3):676-80. PubMed PMID: 2347009. 8: Bellucci C, Gualtieri F, Scapecchi S, Teodori E, Budriesi R, Chiarini A. Negative inotropic and calcium antagonistic activity of alkyl and arylalkyl phosphonates. Farmaco. 1989 Dec;44(12):1167-91. PubMed PMID: 2634406. 9: Yoshino K, Kohno T, Morita T, Tsukamoto G. Organic phosphorus compounds. 2. Synthesis and coronary vasodilator activity of (benzothiazolylbenzyl) phosphonate derivatives. J Med Chem. 1989 Jul;32(7):1528-32. PubMed PMID: 2738888. 10: Chiarini A, Valenti P, Fabbri G, da Re P. Chromosome and xanthone derivatives related to Fostedil. Acta Pharm Suec. 1987;24(5):257-62. PubMed PMID: 3450191. 11: Lynch JJ, Montgomery DG, Lucchesi BR. The effects of calcium entry blockade on the vulnerability of infarcted canine myocardium toward ventricular fibrillation. J Pharmacol Exp Ther. 1986 Nov;239(2):340-5. PubMed PMID: 3490565. 12: Pelc LR, Gross GJ, Brooks HL, Warltier DC. Effects of intracoronary Bay k 8644, a calcium channel agonist, in anesthetized dogs. J Cardiovasc Pharmacol. 1986 Nov-Dec;8(6):1223-8. PubMed PMID: 2434750. 13: Pelc LR, Gross GJ, Warltier DC. Effects of KB-944, a novel calcium antagonist, in several models of canine myocardial ischemia. J Pharmacol Exp Ther. 1986 Jul;238(1):113-8. PubMed PMID: 3723394. 14: Khurmi NS, Bowles MJ, O'Hara MJ, Lahiri A, Raftery EB. Ambulatory monitoring and exercise testing in the evaluation of a new long-acting calcium ion antagonist KB-944 (Fostedil) for the treatment of exertional angina pectoris. Int J Cardiol. 1985 Nov;9(3):289-302. PubMed PMID: 3902675. 15: Bellucci C, Teodori E, Gualtieri F, Piacenza G. Search for new Ca++ antagonists. Lipophilic oximes and phosphonates. Farmaco Sci. 1985 Oct;40(10):730-44. PubMed PMID: 3002848. 16: Iijima T, Morita T, Taira N. Effects of a new calcium entry blocking agent, KB-944, on the membrane potential and currents of mammalian ventricular muscle cells. Arch Int Pharmacodyn Ther. 1985 Sep;277(1):77-82. PubMed PMID: 4062434. 17: Pelc LR, Gross GJ, Warltier DC. Cardiac and systemic hemodynamic actions of the slow channel calcium blocking agent, KB-944. Gen Pharmacol. 1985;16(6):585-90. PubMed PMID: 4085780. 18: Glossmann H, Ferry DR, Goll A, Linn T. Molecular approach to the calcium channel. Adv Myocardiol. 1985;5:41-76. PubMed PMID: 2578683. 19: Thomas EW, Bopp BA. Pharmacokinetics of fostedil, a new calcium antagonist, in beagle dogs following oral and intravenous administration. J Pharm Sci. 1984 Oct;73(10):1400-3. PubMed PMID: 6542139. 20: Patterson E, Montgomery DG, Lynch JJ, Lucchesi BR. Cardiac electrophysiologic actions of KB-944 (Fostedil), a new calcium antagonist, in the anesthetized dog. J Pharmacol Exp Ther. 1984 Sep;230(3):632-40. PubMed PMID: 6540806.

View History

VNI

VNI